Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-09-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
西部证券股份有限公司关于圣湘生物科技股份有限公司关于转让参股公司股权暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from a sponsoring institution (西部证券股份有限公司) regarding an external investment and related party transaction by 圣湘生物科技股份有限公司. It includes comprehensive information about the transaction, the parties involved, financial data of the related entities, the board meeting resolutions, independent directors' opinions, and the sponsor's verification and approval. The document references regulatory rules and compliance with stock exchange listing rules. It is not a brief announcement or a simple notification but a full report on the related party transaction and investment. This type of document fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure about a related party transaction and investment, not an annual report, earnings release, or other specific report types. It is not a report publication announcement since it contains substantive content and detailed analysis rather than just announcing the availability of a report.
2023-09-25 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第十次临时会议相关事宜的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinions on matters to be discussed at the company's 2023 tenth extraordinary board meeting. It references compliance with regulatory rules and discusses specific agenda items such as transfer of equity in an associate company and increase in daily related-party transactions. The document is not a full report but rather a governance-related opinion or announcement related to board matters. It does not contain financial statements or detailed financial data, nor is it a voting result or a proxy solicitation. The content aligns best with Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on corporate governance issues.
2023-09-25 Chinese
圣湘生物科技股份有限公司关于增加2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the increase in the estimated amount of daily related-party transactions for the year 2023 by 圣湘生物科技股份有限公司. It details the nature of the transactions, the approval process by the board, independent directors' opinions, and the impact on the company and shareholders. The document does not contain financial statements or comprehensive financial data but is a regulatory announcement about related-party transactions. It is not an annual report, interim report, or earnings release. It is also not a management change, voting result, or capital change announcement. Given the content and length (3314 characters), it fits best as a Regulatory Filing (RNS) because it is a compliance disclosure about related-party transactions without substantive financial data or report content.
2023-09-25 Chinese
圣湘生物科技股份有限公司关于自愿披露公司相关检测产品获得欧盟CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 圣湘生物科技股份有限公司 regarding the voluntary disclosure of their products obtaining EU CE certification. It details the list of products certified, their intended use, and the potential impact and risks related to this certification. There is no financial data, no mention of financial results, no management or board changes, no voting results, no legal proceedings, no capital or financing updates, and no regulatory compliance filings. The document is an announcement about product certification and its business implications, not a financial report or regulatory filing. It is a formal company announcement informing investors and the public about a significant product certification event and associated risks. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-09-21 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司核心技术人员离职事项的核查意见
Regulatory Filings Classification · 90% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the departure of a core technical staff member at a biotech company. It includes background information, impact assessment, and the sponsor's conclusion that the departure does not adversely affect the company's operations or intellectual property. There are no financial statements, earnings data, or regulatory filings typical of financial reports. The document is a formal opinion or verification related to personnel changes, not a report of board or management changes per se, but it is a regulatory disclosure related to a significant personnel event. Given the nature and content, it best fits under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other categories like MANG (which is for board or senior management changes) or MDA (management discussion).
2023-09-08 Chinese
圣湘生物科技股份有限公司关于公司核心技术人员离职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a core technical personnel from the company. It details the individual's background, the impact of their departure on the company, and the company's measures to mitigate any negative effects. There is no financial data, no mention of financial results, no regulatory filings about financial performance, no voting results, no capital changes, and no legal proceedings. The document is a corporate announcement about management changes specifically related to a key technical staff member, which fits the category of Board/Management Information (MANG). The document length is 2481 characters, which is relatively short but contains substantive information about management changes rather than just a brief notice or report publication announcement. Therefore, the appropriate classification is MANG with high confidence.
2023-09-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.